Next 10 |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 22, 2024) - Faruqi & Faruqi, LLP, a leading national ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 16, 2024) - Faruqi & Faruqi, LLP, a leading national ...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - June 12, 2024) - Faruqi & Faruqi, LLP, a leading national ...
Do you, or did you, own shares of Gritstone bio, Inc. (NASDAQ: GRTS)? Did you purchase your shares between March 9, 2023 and February 29, 2024, inclusive? Did you lose money in your investment in Gritstone bio, Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIR...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-05-09 20:03:10 ET Gritstone bio Inc. (GRTS) Q1 2024 Earnings Conference Call May 09, 2024, 04:30 PM ET Company Participants George MacDougall - Director, Investor Relations and Corporate Communications Andrew Allen - Co-Founder, President, and Chief Executive Of...
2024-05-09 16:26:03 ET More on Gritstone bio Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering Gritstone stock plunges 35% amid Phase 2 data, public offering Gritstone announces proposed public offering Seeking Alpha’s Quant Rating on...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...